| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.2 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | -0.059 | 0.2 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | -0.037 | 0.2 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | -0.037 | 0.2 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | -0.038 | 0.2 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.2 |